Table 3. Myocardial Infarctions (2012 criteria), Overall and by Treatment Group.
| All Participants (n=3876) | Pioglitazone (n=1939) | Placebo (n=1937) | Hazard Ratio (95% CI)* | P† | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| (Events) | Pts. | % | (Events) | Pts. | % | (Events) | Pts. | % | |||
| Any MI | (141) | 128 | 3.3% | (61) | 54 | 2.8% | (80) | 74 | 3.8% | 0.73 (0.51, 1.03) | 0.08 |
| STEMI vs Non-STEMI | |||||||||||
| ST-segment elevation MI | (28) | 28 | 0.7% | (12) | 12 | 0.6% | (16) | 16 | 0.8% | 0.75 (0.35, 1.58) | 0.45 |
| Non-STEMI | (98) | 86 | 2.2% | (44) | 38 | 2.0% | (54) | 48 | 2.5% | 0.79 (0.52, 1.21) | 0.28 |
| Unknown | (15) | 15 | 0.4% | (5) | 5 | 0.3% | (10) | 10 | 0.5% | 0.50 (0.17, 1.46) | 0.20 |
| MI Setting | |||||||||||
| Spontaneous (type 1) | (94) | 86 | 2.2% | (39) | 33 | 1.7% | (55) | 53 | 2.7% | 0.62 (0.40, 0.96) | 0.03 |
| Oxygen imbalance (type 2) | (45) | 43 | 1.1% | (22) | 22 | 1.1% | (23) | 21 | 1.1% | 1.05 (0.58, 1.91) | 0.87 |
| Sudden death (type 3) | (1) | 1 | 0.0% | (0) | 0 | 0.0% | (1) | 1 | 0.1% | ||
| After PCI (type 4a) | (1) | 1 | 0.0% | (0) | 0 | 0.0% | (1) | 1 | 0.1% | ||
| Troponin (Tp) Elevation (xULN) | |||||||||||
| 1-3× (minimal) | (20) | 19 | 0.5% | (9) | 9 | 0.5% | (11) | 10 | 0.5% | 0.90 (0.37, 2.22) | 0.82 |
| 3-10× (mild) | (32) | 32 | 0.8% | (16) | 16 | 0.8% | (16) | 16 | 0.8% | 1.00 (0.50, 2.00) | 0.99 |
| 10-100× (moderate) | (49) | 45 | 1.2% | (24) | 20 | 1.0% | (25) | 25 | 1.3% | 0.80 (0.44, 1.44) | 0.46 |
| >100× (severe) | (39) | 39 | 1.0% | (12) | 12 | 0.6% | (27) | 27 | 1.4% | 0.44 (0.22, 0.87) | 0.02 |
| Unknown | (1) | (0) | (1) | ||||||||
| Fatal MI, STEMI, Tp >100×ULN | (54) | 54 | 1.4% | (18) | 18 | 0.9% | (36) | 36 | 1.9% | 0.50 (0.28, 0.88) | 0.02 |
*
Unadjusted 95% confidence interval (CI).
†
Unadjusted p-value from log-rank test.